Home/Pipeline/KHR‑003

KHR‑003

Solid Tumor Immuno‑Oncology

PreclinicalActive

Key Facts

Indication

Solid Tumor Immuno‑Oncology

Phase

Preclinical

Status

Active

Company

About KAHR Medical

Israeli biotech delivering CRISPR‑derived gene‑editing and mRNA therapeutics for rare diseases and oncology.

View full company profile

Therapeutic Areas

Genetic Disorders Oncology